×
Clearmind Medicine Net Cash Flow 2023-2025 | CMND
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Clearmind Medicine net cash flow from 2023 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
View More
Clearmind Medicine Net Cash Flow 2023-2025 | CMND
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Clearmind Medicine net cash flow from 2023 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$81.3B
Zoetis (ZTS)
$67.7B
Daiichi Sankyo, - (DSNKY)
$46.4B
Takeda Pharmaceutical (TAK)
$46.1B
BeOne Medicines - (ONC)
$31.9B
Sandoz Group AG (SDZNY)
$26.1B
Summit Therapeutics (SMMT)
$21.3B
Merck (MKKGY)
$17.2B
Shionogi (SGIOY)
$14.6B
United Therapeutics (UTHR)
$13.7B
Neurocrine Biosciences (NBIX)
$13.1B
Orion OYJ (ORINY)
$11.7B
IPSEN (IPSEY)
$10.9B
Stevanato Group S.p.A (STVN)
$8B
Corcept Therapeutics (CORT)
$7.2B
Grifols, S.A (GRFS)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.7B
Madrigal Pharmaceuticals (MDGL)
$6.6B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.4B
Hypermarcas (HYPMY)
$2.9B
Crinetics Pharmaceuticals (CRNX)
$2.9B
NewAmsterdam Pharma (NAMS)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.1B
Ocular Therapeutix (OCUL)
$1.9B
Endo (NDOI)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.8B